Stock HALO HALOZYME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
38.77 USD +0.52% Intraday chart for Halozyme Therapeutics, Inc. -0.51% +4.90%
04-25 Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors CI
04-18 Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing MT

Business Summary

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Number of employees: 373

Sales per Business

USD in Million2022Weight2023Weight Delta
Enzymes and Devices
100.0 %
660 100.0 % 829 100.0 % +25.62%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
70.8 %
438 66.4 % 587 70.8 % +34.07%
Switzerland
18.0 %
167 25.3 % 149 18.0 % -10.68%
Belgium
7.0 %
2 0.3 % 58 7.0 % +2,694.73%
All Other Foreign
2.4 %
5 0.8 % 20 2.4 % +272.23%
Japan
1.8 %
48 7.3 % 15 1.8 % -68.51%

Managers

Managers TitleAgeSince
Helen Torley CEO
 Chief Executive Officer 61 05/01/14
Nicole LaBrosse DFI
 Director of Finance/CFO 41 31/12/14
Mark Snyder CMP
 Compliance Officer 57 02/01/22
Steve Knowles CTO
 Chief Tech/Sci/R&D Officer - 31/12/17
Michael LaBarre CTO
 Chief Tech/Sci/R&D Officer 60 15/06/08
Tram Bui IRC
 Investor Relations Contact - 31/12/21
Amy Marinne Fox HRO
 Human Resources Officer - 31/12/19

Members of the board

Members of the board TitleAgeSince
Connie Matsui BRD
 Director/Board Member 70 30/07/06
Jeffrey Henderson CHM
 Chairman 59 04/08/15
Barbara Duncan BRD
 Director/Board Member 59 02/02/23
Helen Torley CEO
 Chief Executive Officer 61 05/01/14
Matthew Posard BRD
 Director/Board Member 56 27/03/13
Akiko Miyashita BRD
 Director/Board Member 68 14/03/22
Bernadette Connaughton BRD
 Director/Board Member 65 09/09/18
Nicole LaBrosse DFI
 Director of Finance/CFO 41 31/12/14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 127,054,240 125,682,266 ( 98.92 %) 0 98.92 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
13.70 %
17,410,754 13.70 % 708 M $
Vanguard Fiduciary Trust Co.
10.44 %
13,259,514 10.44 % 539 M $
Artisan Partners Holdings LP
5.265 %
6,689,058 5.265 % 272 M $
STATE STREET CORPORATION
5.097 %
6,475,549 5.097 % 263 M $
Snyder Capital Management LP
2.920 %
3,709,599 2.920 % 151 M $
AllianceBernstein LP
2.766 %
3,514,028 2.766 % 143 M $
BNY Mellon Investment Adviser, Inc.
2.708 %
3,440,723 2.708 % 140 M $
Macquarie Investment Management Business Trust
2.584 %
3,282,640 2.584 % 134 M $
JPMorgan Investment Management, Inc.
2.423 %
3,078,397 2.423 % 125 M $
Geode Capital Management LLC
2.298 %
2,919,763 2.298 % 119 M $

Company contact information

Halozyme Therapeutics, Inc.

12390 El Camino Real

92130, San Diego

+858 794 8889

http://www.halozyme.com
address Halozyme Therapeutics, Inc.(HALO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Halozyme Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
38.57 USD
Average target price
50.5 USD
Spread / Average Target
+30.93%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
HALOZYME THERAPEUTICS, INC. Stock Halozyme Therapeutics, Inc.
+4.90% 4.9B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-16.67% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. HALO Stock
  4. Company Halozyme Therapeutics, Inc.